A phase II randomized, double-blinded, placebo-controlled, multi-center study of subcutaneous daclizumab in patients with active, relapsing forms of multiple sclerosis.

Trial Profile

A phase II randomized, double-blinded, placebo-controlled, multi-center study of subcutaneous daclizumab in patients with active, relapsing forms of multiple sclerosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Daclizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms CHOICE
  • Most Recent Events

    • 12 Apr 2011 Results presetned at the 63rd Annual Meeting of the American Academy of Neurology, according to a Biogen Idec media release.
    • 05 Apr 2010 Results from two pharmacodynamic substudies will be presented at the 62nd Annual Meeting of the American Academy of Neurology, according to a Facet Biotech media release.
    • 01 Apr 2010 Results published in Lancet Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top